Advertisement

Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms — Physician’s First Watch

Medical News |
February 28, 2014

Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms

By Joe Elia

Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a joint statement from the U.S. Food and Drug Administration and the European Medicines Agency.

The drugs were the subject of a JAMA Internal Medicine study in 2013 that linked their use to a doubled risk for hospitalization for acute pancreatitis.

In the New England Journal of Medicine, the agencies say that they have separately "explored multiple streams of data" and that assertions of a link between the drugs and pancreatic side effects "are inconsistent with the current data." However, they also write that "the FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement